Evidence map›Paper›PMID 18289699›Full record

ReviewVeterinary immunology and immunopathology2008

Human gene therapy vectors derived from feline lentiviruses.

Román A Barraza, Eric M Poeschla

Abstract readReview
In one paragraph

Review in Veterinary immunology and immunopathology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Cell and gene therapy in neuro-oncology.Handbook of clinical neurology · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.Molecular therapy : the journal of the American Society of Gene Therapy · 2010
    Article
  14. Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure.Molecular therapy : the journal of the American Society of Gene Therapy · 2010
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Román A BarrazaMolecular Medicine Program, Guggenheim 18, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States. barraza.roman@mayo.edu
Eric M Poeschla

Funding

Lentiviral Transgenesis of the Aqueous Outflow TractR01EY014411 · NEI · MAYO CLINIC ROCHESTER · PI POESCHLA, ERIC M. · 2003 to 2011
$3.4M
NOVEL LENTIVIRAL VECTORS FOR SUSTAINED GENE EXPRESSIONR01AI047536 · NIAID · MAYO CLINIC ROCHESTER · PI POESCHLA, ERIC M. · 1999 to 2008
$1.8M
Lentiviral Genome ProcessingR21AI047536 · NIAID · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI POESCHLA, ERIC M. · 2003 to 2003
$292k
NEI NIH HHS R01 EY014411NIAID NIH HHS R01 AI047536NIAID NIH HHS R21 AI047536
6 · The paper itself

Abstract

Lentiviral vectors are useful for gene transfer to dividing and nondividing cells. Feline immunodeficiency virus (FIV) vectors transduce most human cell types with good efficiency and may have advantages for clinical gene therapy applications. This article reviews significant progress in the development and refinement of FIV vector systems.

Indexed as

AnimalsCatsGenetic TherapyGenetic VectorsHIV InfectionsHumansImmunodeficiency Virus, FelineTranscription, GeneticTransduction, Genetic

Identifiers

PMID18289699
PMCPMC2443640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.